HCSC coverage for Zepbound (Osa)

What you need to qualify

• BMI of 30 or higher
• Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Medical records confirming diagnosis of obstructive sleep apnea (OSA)
• Polysomnography (PSG) or home sleep apnea test results
• Documentation of AHI >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
• Baseline BMI documentation (>= 30 kg/m2)
• For renewal: documentation of clinical benefit (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale)

Quantity limits

• 2.5 MG/0.5ML vial — 2 mL per 180-day supply (84-day)
• 5 MG/0.5ML vial — 2 mL per 28-day supply
• 7.5 MG/0.5ML vial, 10 MG/0.5ML vial, 12.5 MG/0.5ML vial, 15 MG/0.5ML vial — 4 vials per 28-day supply
• 2.5 MG/0.5ML autoinjector — 4 pens per 180-day supply (84-day)
• 5 MG/0.5ML autoinjector, 7.5 MG/0.5ML autoinjector, 10 MG/0.5ML autoinjector, 12.5 MG/0.5ML autoinjector, 15 MG/0.5ML autoinjector — 4 pens per 28-day supply
• 2.5 MG/0.6ML kwikpen — 1 pen per 180-day supply (84-day)
• 5 MG/0.6ML kwikpen, 7.5 MG/0.6ML kwikpen, 10 MG/0.6ML kwikpen, 12.5 MG/0.6ML kwikpen, 15 MG/0.6ML kwikpen — 1 pen per 28-day supply

Approval and renewal

• Initial approval: 12 months
• Renewal: every 12 months
• To renew, the plan looks for At renewal for OSA indication: patient must have had clinical benefit with Zepbound (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Initial AHI >= 15 and BMI >= 30 requirements are not explicitly re-verified at renewal.

Not covered when

• AHI < 15 events/hour
• Any FDA labeled contraindications to the requested agent

Exceptions

• BCBS_NM_Fully_Insured_or_HIM: May be approved if patient does not have FDA labeled contraindications AND the requested indication is a rare disease AND patient has another FDA labeled indication or compendia-supported indication.
• Ohio_Fully_Insured_or_HIM_SHOP: May be approved if member resides in Ohio, plan is Fully Insured or HIM Shop (SG), no FDA labeled contraindications, AND patient has another FDA labeled or compendia-supported indication OR prescriber submits two articles from major peer-reviewed journals.

Policy note: No PAP/CPAP trial requirement stated. AHI must be >= 15 events/hour from baseline prior to initiation of pharmacotherapy. OSA diagnosis requires medical records. Renewal requires clinical benefit demonstrated (examples: reduction in AHI, decrease in Epworth Sleepiness Scale). Policy applies to all Zepbound formulations (vial, autoinjector, kwikpen).

Policy effective May 18, 2026 · verified June 2, 2026 · source: HCSC_Weight_Management_ProgSum.pdf